Literature DB >> 1455196

Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis.

R Eliakim1, F Karmeli, M Chorev, E Okon, D Rachmilewitz.   

Abstract

The effect of immunosuppressive drugs, 4-aminosalicylic acid (4-ASA), acetyl 5-aminosalicylic acid (5-ASA), and ketotifen on human colonic eicosanoid accumulation was evaluated in view of enhanced accumulation in patients with active ulcerative colitis. Azathioprine (100 micrograms/ml), cyclosporin (100 micrograms/ml), and methotrexate (100 micrograms/ml) significantly inhibited, by 25-35%, prostaglandin E2 (PGE2) accumulation by organ-cultured colonic mucosa of ulcerative colitis patients. Methotrexate was the only immunosuppressive drug that inhibited leukotriene B4 (LTB4) accumulation (50%), whereas azathioprine inhibited the accumulation of leukotriene C4 (LTC4) (25%). 5-ASA and its metabolite, acetyl 5-ASA, inhibited by 20-70% PGE2, LTB4, and LTC4 accumulation in the culture, supporting the contention that acetyl 5-ASA is as active as 5-ASA in these respects. 4-ASA had no effect on any of the eicosanoids. Ketotifen, a mast cell stabilizer, significantly inhibited the accumulation of PGE2, LTB4, and LTC4 by 33-60%. These results suggest a potential, new, unrecognized mode by which the immunomodulators induce part of their therapeutic effects in inflammatory bowel disease and support the contention that acetyl 5-ASA is as active as 5-ASA. The results obtained also indicate that ketotifen, used effectively in the prevention of bronchial asthma, inhibits the accumulation of colonic eicosanoids and, thus, may be of value in the treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455196     DOI: 10.3109/00365529209000172

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  13 in total

Review 1.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

2.  Therapeutic effects of ecabet sodium, an antiulcer drug, on dextran sodium sulfate-induced ulcerative colitis in rats.

Authors:  Tsunehisa Noto; Hiroshi Yamada; Takashi Inui; Kayoko Okuyama; Ayako Watanable; Isami Kimura; Masaaki Nagasaki
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

3.  Ketotifen therapy for acute ulcerative colitis in children: a pilot study.

Authors:  N L Jones; C M Roifman; A M Griffiths; P Sherman
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

4.  Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits.

Authors:  M J Naya; D Pereboom; J Ortego; J O Alda; A Lanas
Journal:  Gut       Date:  1997-02       Impact factor: 23.059

Review 5.  The future potential of eicosanoids and their inhibitors in paediatric practice.

Authors:  T Shimizu
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

6.  Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.

Authors:  Verónica Ramírez-Alcántara; Marshall H Montrose
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

Review 7.  Key role of mast cells and their major secretory products in inflammatory bowel disease.

Authors:  Shao-Heng He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

8.  Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.

Authors:  Glen A Doherty; Mark A Peppercorn
Journal:  Clin Exp Gastroenterol       Date:  2009-12-08

Review 9.  Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

Review 10.  Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives.

Authors:  F Scaldaferri; V Petito; L Lopetuso; G Bruno; V Gerardi; G Ianiro; A Sgambato; A Gasbarrini; G Cammarota
Journal:  Mediators Inflamm       Date:  2013-05-08       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.